Czech National Bank Has $26.80 Million Stake in Stryker Co. (NYSE:SYK)

Czech National Bank boosted its stake in Stryker Co. (NYSE:SYK - Free Report) by 6.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 74,430 shares of the medical technology company's stock after buying an additional 4,587 shares during the period. Czech National Bank's holdings in Stryker were worth $26,799,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of SYK. Main Street Financial Solutions LLC boosted its stake in Stryker by 19.8% during the 2nd quarter. Main Street Financial Solutions LLC now owns 709 shares of the medical technology company's stock valued at $241,000 after purchasing an additional 117 shares in the last quarter. Federated Hermes Inc. grew its holdings in Stryker by 16.2% during the second quarter. Federated Hermes Inc. now owns 113,916 shares of the medical technology company's stock worth $38,760,000 after acquiring an additional 15,882 shares during the period. HBK Sorce Advisory LLC bought a new stake in Stryker in the second quarter worth about $241,000. Parallel Advisors LLC lifted its holdings in Stryker by 2.0% in the 2nd quarter. Parallel Advisors LLC now owns 15,311 shares of the medical technology company's stock valued at $5,209,000 after acquiring an additional 300 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its position in shares of Stryker by 11.9% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 35,282 shares of the medical technology company's stock valued at $12,005,000 after purchasing an additional 3,765 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Stock Down 1.3 %

Shares of Stryker stock traded down $4.70 during midday trading on Monday, reaching $360.96. 1,400,728 shares of the company's stock traded hands, compared to its average volume of 1,302,047. The company has a market cap of $137.60 billion, a price-to-earnings ratio of 38.69, a price-to-earnings-growth ratio of 2.82 and a beta of 0.95. Stryker Co. has a 52 week low of $307.23 and a 52 week high of $398.20. The company's 50 day simple moving average is $375.28 and its 200 day simple moving average is $358.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The company had revenue of $5.49 billion during the quarter, compared to analysts' expectations of $5.37 billion. During the same quarter in the previous year, the firm earned $2.46 earnings per share. The business's quarterly revenue was up 11.9% compared to the same quarter last year. Equities analysts expect that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.93%. The ex-dividend date is Tuesday, December 31st. This is an increase from Stryker's previous quarterly dividend of $0.80. Stryker's dividend payout ratio (DPR) is 36.01%.

Insiders Place Their Bets

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares of the company's stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.90% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of Stryker from $375.00 to $420.00 and gave the stock an "overweight" rating in a report on Wednesday, October 30th. Robert W. Baird upped their price target on Stryker from $378.00 to $405.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. Wells Fargo & Company lifted their target price on Stryker from $405.00 to $427.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Citigroup upped their target price on Stryker from $411.00 to $450.00 and gave the company a "buy" rating in a report on Wednesday, December 11th. Finally, UBS Group boosted their price objective on Stryker from $366.00 to $370.00 and gave the stock a "neutral" rating in a report on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $405.80.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.